Videos
What’s next in the PCSK9 field: small interference RNA therapeutics
ESC Congress 2015, London, 30th August 2015 There were promising data with the reformulated small interference RNA (siRNA) therapeutic targeting PCSK9 (ALN-PCSsc). The study results indicate potential for a quarterly or even twice-yearly subcutaneous injection regimen. Previously a proof of concept Phase I study showed the…
read more »
Start treatment early: Maximise benefit
FH is the most common inherited disease in the world – affecting about 30 million people worldwide – of whom only about 1% have been diagnosed. Therefore, it is critically important there is a global effort to start treatment early to prevent children ever developing…
read more »
Dutch experience – Improving detection and care
In Europe, the Netherlands has proved that a concerted and integrated effort delivers effective detection of families at risk through cascade screening combined with early treatment – including considering statin therapy – in children the prognosis of people with FH is being significantly improved. Dr…
read more »
How will PCSK9 inhibitors be used in practice?
Professor Steven Nicholls, Professor of Cardiology at the University of Adelaide and the inaugural SAHMRI Heart Foundation Heart Health Theme Leader at the South Australian Health and Medical Research Institute, Australia, discusses the patients in whom these new treatments will be used initially and speculates…
read more »
New cholesterol lowering drugs in news
The new PCSK9 inhibitors – drugs which reduce LDL-Cholesterol to previously manageable levels – are being reviewed by regulatory authorities worldwide. Why are they creating so much interest? Professor Philip Barter, President of the International Atherosclerosis Society comments.
read more »
Consider FH in young heart attack patients
New data from EUROASPIRE IV shows that about one in 12 heart attack patients have probable familial hypercholesterolaemia (FH, inherited high cholesterol). FH prevalence was even higher in those aged <50 years, affecting one in 5 patients. FH is a common inherited hypercholesterolaemia, with heterozygous…
read more »
Making premature CHD history
Dr Samuel Gidding discusses how treating children with FH early can make premature CHD history
read more »
How to identify children with FH
Dr Samuel Gidding discusses how to identify children with FH
read more »
Safety of lowering LDL-C
Dr Albert Wiegman discusses the safety of lowering LDL C in FH children
read more »
EAS Consensus Panel on Paediatric FH
Dr Raul Santos discusses the EAS Consensus Panel statement on FH in children – Spanish Dr Raul Santos discusses the EAS Consensus Panel statement on FH in children – Portuguese
read more »
ISA 2015: Evolocumab in TAUSSIG homozygous FH cohort
News from one of the largest cohort of patients with homozygous familial hypercholesterolaemia (FH, inherited high cholesterol) in the TAUSSIG (Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders) study strengthens the data for evolocumab.1 In 100 patients with homozygous FH,…
read more »
New era in cholesterol-lowering? PCSK9 inhibitors soon available?
European authority (CHMP) has recommended regulatory approval of the first PCSK9 inhibitor, opening the way to a new era of lowering LDL-cholesterol treatment for people with a high risk of heart attacks and strokes. The importance of this development and possible implications for patients with…
read more »
ISA 2015: EAS Consensus Panel publishes Position Statement on Paediatric Familial Hypercholesterolaemia
The European Atherosclerosis Society (EAS) Consensus Panel has today published a new position paper aiming to raise awareness of the urgent need to identify and treat children with familial hypercholesterolaemia (FH) early. The EAS Consensus Panel position paper also provides clinical guidance for the diagnosis…
read more »
FH in Argentina: Why the European Atherosclerosis Society FH Studies Collaboration (EAS-FHSC) is key
PCSK9 Forum caught up with Dr Pablo Corral, ICM Institute Medical Clinic, Buenos Aires, Argentina during the 83rd European Atherosclerosis Society (EAS) Congress in Glasgow, Scotland. The status of FH management in Argentina has improved over the last 2 years. There has been a new…
read more »
European Atherosclerosis Society Consensus Panel on statin-associated muscle symptoms: Professor Erik Stroes, Academic Medical Center, the Netherlands
PCSK9 Forum caught up with Professor Stroes at the 83rd Congress of the European Atherosclerosis Society (EAS), Glasgow 22-25 March, 2015 to discuss this recent EAS Consensus Panel paper. Statin-associated muscle symptoms (SAMS) were very much the hot topic at EAS Glasgow, reflecting the high…
read more »
Loss of function mutations in PCSK9: the trigger for therapeutic development
Studies of mutations of PCSK9 function have identified a new therapeutic target for reducing very high levels of low density lipoprotein cholesterol (LDL-C). Professor Anne Tybjaerg-Hansen describes this opportunity.
read more »
Does PCSK9 have effects beyond the liver and if so, what is the evidence?
Laboratory research conducted in France shows that PCSK9 may have effects beyond its primary action in the liver, where its inhibition significantly lowers low density lipoprotein cholesterol (LDL-C). These studies also provide reassuring data about the probable safety of these new therapies, Professor Bertrand Cariou…
read more »
Familial hypercholesterolaemia: putting the patient first
Patients and their families must be proactively involved in the identification and treatment of people with familial hypercholesterolaemia (FH) – a group whose severely raised low density lipoprotein cholesterol (LDL-C) puts them at a very high risk of premature death. Founder and CEO of the…
read more »
Will the PCSK9 monoclonal antibodies replace other lipid lowering treatment used with statins
Where will the new PCSK9 inhibitors fit into the treatment of people whose raised low density lipoprotein cholesterol (LDL-C) puts them at high risk of cardiovascular disease? Leading researcher, Professor Frederick Raal discusses this important question.
read more »
Lowering LDL-C: How low and for how long?
Treatment to reduce low density lipoprotein cholesterol (LDL-C) should be started in teenage years in people with very high risk of cardiovascular death or events e.g. heart attacks. There is substantial evidence showing significant benefits if LDL-C is reduced by about 50%, Professor Evan Stein…
read more »
